Pacific Island Pharmacovigilance: The Need for a Different Approach

Research output: Contribution to journal › Letter › Research › peer-review

Standard

Pacific Island Pharmacovigilance : The Need for a Different Approach. / McEwen, John; Vestergaard, Lasse S.; Sanburg, Amanda L C.

In: Drug Safety, Vol. 39, No. 10, 10.2016, p. 891-894.

Research output: Contribution to journal › Letter › Research › peer-review

Harvard

McEwen, J, Vestergaard, LS & Sanburg, ALC 2016, 'Pacific Island Pharmacovigilance: The Need for a Different Approach', Drug Safety, vol. 39, no. 10, pp. 891-894. https://doi.org/10.1007/s40264-016-0439-4

APA

McEwen, J., Vestergaard, L. S., & Sanburg, A. L. C. (2016). Pacific Island Pharmacovigilance: The Need for a Different Approach. Drug Safety, 39(10), 891-894. https://doi.org/10.1007/s40264-016-0439-4

Vancouver

McEwen J, Vestergaard LS, Sanburg ALC. Pacific Island Pharmacovigilance: The Need for a Different Approach. Drug Safety. 2016 Oct;39(10):891-894. https://doi.org/10.1007/s40264-016-0439-4

Author

McEwen, John ; Vestergaard, Lasse S. ; Sanburg, Amanda L C. / Pacific Island Pharmacovigilance : The Need for a Different Approach. In: Drug Safety. 2016 ; Vol. 39, No. 10. pp. 891-894.

Bibtex

@article{c20950a72954406f9630e1a92684491a,
title = "Pacific Island Pharmacovigilance: The Need for a Different Approach",
abstract = "Many Pacific Island countries (PICs) are recipients of funding support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). However, most of these countries cannot be expected to meet Global Fund and World Health Organization (WHO) minimum requirements for a functioning pharmacovigilance (PV) system. We argue that a different approach is required to move PV forward in such countries. Although the long-term aim is to build adequate national PV capacity, we propose an approach in which resources are focused initially towards ensuring a proper system for the reporting of “problems with medicines” such as substandard and counterfeit products. The limited health system resources in these countries require that PV will be supported by some of the organizations also giving funding aid for the supply of medicines.",
author = "John McEwen and Vestergaard, {Lasse S.} and Sanburg, {Amanda L C}",
year = "2016",
month = oct,
doi = "10.1007/s40264-016-0439-4",
language = "English",
volume = "39",
pages = "891--894",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "10",

}

RIS

TY - JOUR

T1 - Pacific Island Pharmacovigilance

T2 - The Need for a Different Approach

AU - McEwen, John

AU - Vestergaard, Lasse S.

AU - Sanburg, Amanda L C

PY - 2016/10

Y1 - 2016/10

N2 - Many Pacific Island countries (PICs) are recipients of funding support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). However, most of these countries cannot be expected to meet Global Fund and World Health Organization (WHO) minimum requirements for a functioning pharmacovigilance (PV) system. We argue that a different approach is required to move PV forward in such countries. Although the long-term aim is to build adequate national PV capacity, we propose an approach in which resources are focused initially towards ensuring a proper system for the reporting of “problems with medicines” such as substandard and counterfeit products. The limited health system resources in these countries require that PV will be supported by some of the organizations also giving funding aid for the supply of medicines.

AB - Many Pacific Island countries (PICs) are recipients of funding support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). However, most of these countries cannot be expected to meet Global Fund and World Health Organization (WHO) minimum requirements for a functioning pharmacovigilance (PV) system. We argue that a different approach is required to move PV forward in such countries. Although the long-term aim is to build adequate national PV capacity, we propose an approach in which resources are focused initially towards ensuring a proper system for the reporting of “problems with medicines” such as substandard and counterfeit products. The limited health system resources in these countries require that PV will be supported by some of the organizations also giving funding aid for the supply of medicines.

U2 - 10.1007/s40264-016-0439-4

DO - 10.1007/s40264-016-0439-4

M3 - Letter

C2 - 27364632

AN - SCOPUS:84976474309

VL - 39

SP - 891

EP - 894

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 10

ER -

ID: 169080825